D C Johannessen
Overview
Explore the profile of D C Johannessen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S, et al.
N Engl J Med
. 2013 Jul;
369(3):213-23.
PMID: 23863050
Background: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the...
2.
Lonning P, Geisler J, Johannessen D, Gschwind H, Waldmeier F, Schneider W, et al.
J Steroid Biochem Mol Biol
. 2001 May;
77(1):39-47.
PMID: 11358673
Formestane (Lentaron(R), 4-hydroxyandrostenedione) is a steroidal aromatase inhibitor used for treatment of advanced breast cancer. Clinically, it is administered as a depot form once fortnightly by intramuscular (i.m.) injection. To...
3.
Anker G, Refsum H, Ueland P, Johannessen D, Lien E, Lonning P
Clin Chem
. 1999 Feb;
45(2):252-6.
PMID: 9931048
In this study, we evaluated the effect of estrogen suppression with three aromatase inhibitors, aminoglutethimide (n = 30), formestane (n = 12), and exemestane (n = 10), and the progestin...
4.
Berntsen H, Lonning P, Ekse D, Netteland B, Johannessen D, Berge R, et al.
Cancer Chemother Pharmacol
. 1998 Jun;
42(1):46-52.
PMID: 9619757
Purpose: Elevated cellular glutathione has been associated with resistance to cancer chemotherapy. Treatment with the aromatase inhibitor aminoglutethimide increases the concentration of gamma-glutamyl transpeptidase (gamma-GT) in breast cancer patients. This...
5.
Johannessen D, Engan T, Di Salle E, Zurlo M, Paolini J, Ornati G, et al.
Clin Cancer Res
. 1997 Jul;
3(7):1101-8.
PMID: 9815789
Clinical and endocrinological effects of exemestane (6-methylenandrosta-1,4-diene-3,17-dione; PNU 155971) were evaluated in an open Phase I study. Thirteen postmenopausal women suffering from advanced breast cancer received exemestane in escalating doses...
6.
Lonning P, Geisler J, Johannessen D, Ekse D
J Steroid Biochem Mol Biol
. 1997 Apr;
61(3-6):255-60.
PMID: 9365198
Aromatase inhibition is a well-defined treatment option for postmenopausal breast cancer. Although several aromatase inhibitors such as aminoglutethimide, formestane and fadrozole have been found to inhibit in vivo aromatization by...
7.
Geisler J, Johannessen D, Anker G, Lonning P
Eur J Cancer
. 1996 May;
32A(5):789-92.
PMID: 9081355
We studied the clinical and endocrine effects of the aromatase inhibitor formestane (4-hydroxyandrostenedione, 4-OHA) in heavily pretreated breast cancer patients (median number of previous endocrine treatments 2, range 1-4). Of...
8.
Lonning P, Helle S, Johannessen D, Ekse D, Adlercreutz H
Breast Cancer Res Treat
. 1996 Jan;
39(3):335-41.
PMID: 8877014
The influence of plasma estrogen levels on disease-free interval (time from primary treatment to first relapse, DFI) in breast cancer patients is not known. Any relation between plasma estrogens and...
9.
Lonning P, Johannessen D, Lien E, Ekse D, Fotsis T, Adlercreutz H
J Steroid Biochem Mol Biol
. 1995 May;
52(5):491-6.
PMID: 7748814
Estrone sulphate (E1S) may be an important estrogen source in breast cancers, particularly in postmenopausal women. Recent studies have shown that tamoxifen inhibits the uptake and metabolism of E1S to...
10.
Engan T, Krane J, Johannessen D, Lonning P, KVINNSLAND S
Breast Cancer Res Treat
. 1995 Jan;
36(3):287-97.
PMID: 8573711
Side-effects following long-term endocrine therapy might have clinical implications. The aim of this study was to study potential methods to detect effects on plasma induced by hormonal therapies. The composite...